| Dependence on glutamine uptake and glutamine addiction characterize myeloma cells: a new attractive target M Bolzoni, M Chiu, F Accardi, R Vescovini, I Airoldi, P Storti, K Todoerti, ... Blood, The Journal of the American Society of Hematology 128 (5), 667-679, 2016 | 174 | 2016 |
| Mechanism of action of bortezomib and the new proteasome inhibitors on myeloma cells and the bone microenvironment: impact on myeloma‐induced alterations of bone remodeling F Accardi, D Toscani, M Bolzoni, B Dalla Palma, F Aversa, N Giuliani BioMed research international 2015 (1), 172458, 2015 | 146 | 2015 |
| Hypoxia-inducible factor (HIF)-1α suppression in myeloma cells blocks tumoral growth in vivo inhibiting angiogenesis and bone destruction P Storti, M Bolzoni, G Donofrio, I Airoldi, D Guasco, D Toscani, E Martella, ... Leukemia 27 (8), 1697-1706, 2013 | 138 | 2013 |
| Multiple myeloma-derived exosomes are enriched of amphiregulin (AREG) and activate the epidermal growth factor pathway in the bone microenvironment leading to osteoclastogenesis S Raimondo, L Saieva, E Vicario, M Pucci, D Toscani, M Manno, ... Journal of hematology & oncology 12, 1-15, 2019 | 116 | 2019 |
| New insights into osteogenic and chondrogenic differentiation of human bone marrow mesenchymal stem cells and their potential clinical applications for bone regeneration in … N Giuliani, G Lisignoli, M Magnani, C Racano, M Bolzoni, B Dalla Palma, ... Stem cells international 2013 (1), 312501, 2013 | 111 | 2013 |
| NAD+-Metabolizing Ectoenzymes in Remodeling Tumor–Host Interactions: The Human Myeloma Model AL Horenstein, A Chillemi, V Quarona, A Zito, I Roato, F Morandi, ... Cells 4 (3), 520-537, 2015 | 108 | 2015 |
| Adenosine generated in the bone marrow niche through a CD38-mediated pathway correlates with progression of human myeloma AL Horenstein, V Quarona, D Toscani, F Costa, A Chillemi, V Pistoia, ... Molecular medicine 22, 694-704, 2016 | 105 | 2016 |
| Immunomodulatory drugs lenalidomide and pomalidomide inhibit multiple myeloma-induced osteoclast formation and the RANKL/OPG ratio in the myeloma microenvironment targeting the … M Bolzoni, P Storti, S Bonomini, K Todoerti, D Guasco, D Toscani, ... Experimental hematology 41 (4), 387-397. e1, 2013 | 93 | 2013 |
| Microvesicles released from multiple myeloma cells are equipped with ectoenzymes belonging to canonical and non-canonical adenosinergic pathways and produce adenosine from ATP … F Morandi, D Marimpietri, AL Horenstein, M Bolzoni, D Toscani, F Costa, ... Oncoimmunology 7 (8), e1458809, 2018 | 89 | 2018 |
| Expression of CD38 in myeloma bone niche: A rational basis for the use of anti-CD38 immunotherapy to inhibit osteoclast formation F Costa, D Toscani, A Chillemi, V Quarona, M Bolzoni, V Marchica, ... Oncotarget 8 (34), 56598, 2017 | 71 | 2017 |
| The osteoblastic niche in the context of multiple myeloma D Toscani, M Bolzoni, F Accardi, F Aversa, N Giuliani Annals of the New York Academy of Sciences 1335 (1), 45-62, 2015 | 68 | 2015 |
| Myeloma cells inhibit non-canonical wnt co-receptor ror2 expression in human bone marrow osteoprogenitor cells: effect of wnt5a/ror2 pathway activation on the osteogenic … M Bolzoni, G Donofrio, P Storti, D Guasco, D Toscani, M Lazzaretti, ... Leukemia 27 (2), 451-463, 2013 | 65 | 2013 |
| The proteasome inhibitor bortezomib maintains osteocyte viability in multiple myeloma patients by reducing both apoptosis and autophagy: a new function for proteasome inhibitors D Toscani, C Palumbo, B Dalla Palma, M Ferretti, M Bolzoni, V Marchica, ... Journal of Bone and Mineral Research 31 (4), 815-827, 2016 | 58 | 2016 |
| IL21R expressing CD14+ CD16+ monocytes expand in multiple myeloma patients leading to increased osteoclasts M Bolzoni, D Ronchetti, P Storti, G Donofrio, V Marchica, F Costa, ... Haematologica 102 (4), 773, 2017 | 45 | 2017 |
| Role of osteocytes in myeloma bone disease: anti-sclerostin antibody as new therapeutic strategy D Toscani, M Bolzoni, M Ferretti, C Palumbo, N Giuliani Frontiers in immunology 9, 2467, 2018 | 44 | 2018 |
| Lenalidomide increases human dendritic cell maturation in multiple myeloma patients targeting monocyte differentiation and modulating mesenchymal stromal cell inhibitory properties F Costa, R Vescovini, M Bolzoni, V Marchica, P Storti, D Toscani, ... Oncotarget 8 (32), 53053, 2017 | 37 | 2017 |
| Role of 1q21 in multiple myeloma: from pathogenesis to possible therapeutic targets J Burroughs Garcìa, RA Eufemiese, P Storti, G Sammarelli, L Craviotto, ... Cells 10 (6), 1360, 2021 | 33 | 2021 |
| Myeloma cells deplete bone marrow glutamine and inhibit osteoblast differentiation limiting asparagine availability M Chiu, D Toscani, V Marchica, G Taurino, F Costa, MG Bianchi, ... Cancers 12 (11), 3267, 2020 | 33 | 2020 |
| Bone marrow CX3CL1/fractalkine is a new player of the pro-angiogenic microenvironment in multiple myeloma patients V Marchica, D Toscani, A Corcione, M Bolzoni, P Storti, R Vescovini, ... Cancers 11 (3), 321, 2019 | 33 | 2019 |
| Novel targets for the treatment of relapsing multiple myeloma N Giuliani, F Accardi, V Marchica, B Dalla Palma, P Storti, D Toscani, ... Expert Review of Hematology 12 (7), 481-496, 2019 | 32 | 2019 |
